Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon
- PMID: 20519594
- PMCID: PMC2877405
- DOI: 10.4269/ajtmh.2010.09-0521
Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon
Abstract
Despite being free of charge, treatment adherence to 7-day primaquine for the radical cure of Plasmodium vivax was estimated at 62.2% among patients along the Iquitos-Nauta road in the Peruvian Amazon. The principal reason for non-adherence was the perceived adverse effects related to local humoral illness conceptions that hold that malaria produces a hot state of body, which is further aggravated by the characteristically hot medical treatment. Notably, patients were willing to adhere to the first 3 days of treatment during which symptoms are most apparent and include the characteristic chills. Nevertheless, as symptoms abate, the perceived aggravating characteristics of the medication outweigh the perceived advantages of treatment adherence. Improving community awareness about the role of primaquine to prevent further malaria transmission and fostering a realistic system of direct observed treatment intake, organized at community level, can be expected to improve adherence to the radical cure of P. vivax in this area.
Figures
Similar articles
-
Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.Lancet Infect Dis. 2024 Jun;24(6):629-638. doi: 10.1016/S1473-3099(24)00074-4. Epub 2024 Mar 4. Lancet Infect Dis. 2024. PMID: 38452779 Free PMC article.
-
Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.PLoS Med. 2021 Jun 1;18(6):e1003614. doi: 10.1371/journal.pmed.1003614. eCollection 2021 Jun. PLoS Med. 2021. PMID: 34061843 Free PMC article.
-
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.Lancet. 2019 Sep 14;394(10202):929-938. doi: 10.1016/S0140-6736(19)31285-1. Epub 2019 Jul 18. Lancet. 2019. PMID: 31327563 Free PMC article. Clinical Trial.
-
Management of relapsing Plasmodium vivax malaria.Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31. Expert Rev Anti Infect Ther. 2016. PMID: 27530139 Free PMC article. Review.
-
Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.Malar J. 2024 May 13;23(1):145. doi: 10.1186/s12936-024-04924-z. Malar J. 2024. PMID: 38741094 Free PMC article. Review.
Cited by
-
Malaria risk assessment and mapping using satellite imagery and boosted regression trees in the Peruvian Amazon.Sci Rep. 2019 Oct 23;9(1):15173. doi: 10.1038/s41598-019-51564-4. Sci Rep. 2019. PMID: 31645604 Free PMC article.
-
Spatial patterns and climate drivers of malaria in three border areas of Brazil, Venezuela and Guyana, 2016-2018.Sci Rep. 2022 Jun 29;12(1):10995. doi: 10.1038/s41598-022-14012-4. Sci Rep. 2022. PMID: 35768450 Free PMC article.
-
The history of 20th century malaria control in Peru.Malar J. 2013 Aug 30;12:303. doi: 10.1186/1475-2875-12-303. Malar J. 2013. PMID: 24001096 Free PMC article. Review.
-
Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.Lancet Infect Dis. 2024 Jun;24(6):629-638. doi: 10.1016/S1473-3099(24)00074-4. Epub 2024 Mar 4. Lancet Infect Dis. 2024. PMID: 38452779 Free PMC article.
-
Use of antimicrobials and other medical products in an ethnic minority context of South-Central Vietnam: A qualitative study of vulnerability.PLOS Glob Public Health. 2024 Apr 9;4(4):e0002982. doi: 10.1371/journal.pgph.0002982. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38593159 Free PMC article.
References
-
- Oficina General de Epidemiologia, DIRESA Loreto Análisis de la situación de salud de la region Loreto año 2007. 2008. http://www.dge.gob.pe/asis_inddep.php Available at. Accessed October 25, 2009.
-
- Baird KJ, Rieckmann K. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19:115–120. - PubMed
-
- Burke L, Ockene I. Compliance in Health Care and Research. New York: Futura; 2001.
-
- Einarson T. Drug-related hospital admissions. Ann Pharmacother. 1993;27:832–840. - PubMed
-
- Yeung S, White N. How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health. 2005;10:121–138. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources